1
|
Shiozumi T, Okada N, Matsuyama T, Yamahata Y, Ohta B. Anti-Muscle-Specific Kinase (MuSK) Antibody-Positive Myasthenia Gravis Presenting With Dyspnea in an Elderly Woman: A Case Report. Cureus 2023; 15:e50480. [PMID: 38222201 PMCID: PMC10786710 DOI: 10.7759/cureus.50480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/13/2023] [Indexed: 01/16/2024] Open
Abstract
Myasthenia gravis (MG) is an autoimmune disease and represents one of the most common disorders associated with neuromuscular transmission defects. Within MG, the anti-muscle-specific kinase antibody-positive subtype (MuSK-positive MG) is rare. While it shares similarities with the common form of MG by presenting with ocular weakness, MuSK-positive MG typically presents with more atypical symptoms. Although MuSK-positive MG can lead to type 2 respiratory failure due to respiratory weakness, there have been limited reports where initial presentation involves only respiratory compromise. This study details a case of MuSK-positive MG presenting dyspnea. An 84-year-old female presented to the emergency department due to a three-day history of progressive respiratory distress, characterized by increased respiratory effort and shallow breathing, resulting in a diagnosis of type 2 respiratory failure. Despite the absence of neurological abnormalities, she tested positive for anti-muscle-specific kinase antibodies, confirming a diagnosis of MuSK-positive MG. This case highlights the significance of considering MG in the context of type 2 respiratory failure, even in the absence of typical neurological symptoms, especially in elderly patients.
Collapse
Affiliation(s)
- Tadaharu Shiozumi
- Department of Emergency Medicine, Kyoto Prefectural University of Medicine, Kyoto, JPN
| | - Nobunaga Okada
- Department of Emergency Medicine, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, JPN
| | - Tasuku Matsuyama
- Department of Emergency Medicine, Kyoto Prefectural University of Medicine, Kyoto, JPN
| | - Yoshihiro Yamahata
- Department of Emergency Medicine, Kyoto Prefectural University of Medicine, Kyoto, JPN
| | - Bon Ohta
- Department of Emergency Medicine, Kyoto Prefectural University of Medicine, Kyoto, JPN
| |
Collapse
|
2
|
Pietris J, Madike R, Lam A, Al Sharifi A, Bacchi S, Gupta AK, Kovoor JG, Chan W. Cogan's Lid Twitch for Myasthenia Gravis: A Systematic Review. Semin Ophthalmol 2023; 38:727-736. [PMID: 37166275 DOI: 10.1080/08820538.2023.2211134] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 04/17/2023] [Accepted: 04/18/2023] [Indexed: 05/12/2023]
Abstract
INTRODUCTION Myasthenia gravis is an autoimmune condition affecting the neuromuscular junction of skeletal muscles and may be difficult to diagnose. Several clinical signs may have diagnostic utility, including Cogan's lid twitch. This systematic review aims to synthesise the literature on the accuracy of Cogan's lid twitch for diagnosing myasthenia gravis. METHODS A systematic search of the databases PubMed/MEDLINE, Embase and CENTRAL was performed from inception to August 2022. Risk of bias analysis and data extraction were performed in accordance with the PRISMA 2020 guidelines. RESULTS Seven articles satisfied the inclusion criteria. The results showed that for the diagnosis of myasthenia gravis, Cogan's lid twitch has a sensitivity between 50% and 99% and specificity between 75% and 100%. CONCLUSIONS Cogan's lid twitch is a physical examination finding with moderate diagnostic performance in the diagnosis of myasthenia gravis with ocular involvement. Future studies may seek to evaluate the performance of Cogan's lid twitch in conjunction with other signs of myasthenia gravis with ocular involvements, such as fatigable ptosis or a positive icepack test.
Collapse
Affiliation(s)
- James Pietris
- Faculty of Medicine, University of Queensland, Herston, Australia
- Princess Alexandra Hospital, Woolloongabba, Australia
| | - Reema Madike
- Faculty of Medicine, University of Adelaide, Adelaide, SA, Australia
- Department of Ophthalmology, Royal Adelaide Hospital, Adelaide, SA, Australia
| | - Antoinette Lam
- Faculty of Medicine, University of Adelaide, Adelaide, SA, Australia
- Department of Ophthalmology, Royal Adelaide Hospital, Adelaide, SA, Australia
| | - Ali Al Sharifi
- Faculty of Medicine, University of Adelaide, Adelaide, SA, Australia
- Department of Ophthalmology, Royal Adelaide Hospital, Adelaide, SA, Australia
| | - Stephen Bacchi
- Faculty of Medicine, University of Adelaide, Adelaide, SA, Australia
- Department of Ophthalmology, Royal Adelaide Hospital, Adelaide, SA, Australia
| | - Aashray K Gupta
- Faculty of Medicine, University of Adelaide, Adelaide, SA, Australia
- Gold Coast University Hospital, Southport, Australia
| | - Joshua G Kovoor
- Faculty of Medicine, University of Adelaide, Adelaide, SA, Australia
- Department of Ophthalmology, Royal Adelaide Hospital, Adelaide, SA, Australia
| | - WengOnn Chan
- Faculty of Medicine, University of Adelaide, Adelaide, SA, Australia
- Department of Ophthalmology, Royal Adelaide Hospital, Adelaide, SA, Australia
| |
Collapse
|
3
|
Shah LK, Pant B, Mony N, Mishra S, Gaire J, Sharma S. COVID-19 and Sepsis in an Atypical Case of Mixed Connective Tissue Disorder Presenting With a Myasthenic Crisis. Cureus 2022; 14:e29092. [PMID: 36249611 PMCID: PMC9556605 DOI: 10.7759/cureus.29092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/12/2022] [Indexed: 11/08/2022] Open
Abstract
Myasthenia gravis (MG) is an autoimmune illness that causes neuromuscular junctions to be damaged by anti-acetylcholine receptor antibodies. It is a very rare condition that is more common among women. Fatigable fluctuating diplopia or ptosis is the characteristic early appearance of this condition. Dysphagia or dysphonia may be present in rare cases. This illness can affect any group of skeletal muscles, including those in the neck and upper limbs. It can also affect the muscles that help you breathe, which can lead to breathing failure. We present a case of a 20-year-old female diagnosed with mixed connective tissue disease presenting with acute respiratory failure as the initial presentation of MG. Clinicians have to have a high index of suspicion for myasthenia when patients arrive with fatigable muscle weakness. This will cut down on the amount of money spent on investigations and the risk of morbidity.
Collapse
|
4
|
Chamani S, Moossavi M, Naghizadeh A, Abbasifard M, Majeed M, Johnston TP, Sahebkar A. Immunomodulatory effects of curcumin in systemic autoimmune diseases. Phytother Res 2022; 36:1616-1632. [PMID: 35302258 DOI: 10.1002/ptr.7417] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 01/27/2022] [Accepted: 01/30/2022] [Indexed: 12/23/2022]
Abstract
Systemic autoimmune diseases like rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus represent various autoimmune conditions identified by immune system dysregulation. The activation of immune cells, auto-antigen outbreak, inflammation, and multi-organ impairment is observed in these disorders. The immune system is an essential complex network of cells and chemical mediators which defends the organism's integrity against foreign microorganisms, and its precise operation and stability are compulsory to avoid a wide range of medical complications. Curcumin is a phenolic ingredient extracted from turmeric and belongs to the Zingiberaceae, or ginger family. Curcumin has multiple functions, such as inhibiting inflammation, oxidative stress, tumor cell proliferation, cell death, and infection. Nevertheless, the immunomodulatory influence of curcumin on immunological reactions/processes remains mostly unknown. In the present narrative review, we sought to provide current information concerning the preclinical and clinical uses of curcumin in systemic autoimmune diseases.
Collapse
Affiliation(s)
- Sajjad Chamani
- Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences (BUMS), Birjand, Iran.,Department of Immunology, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran
| | - Maryam Moossavi
- Department of Molecular Medicine, Birjand University of Medical Sciences, Birjand, Iran
| | - Ali Naghizadeh
- Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences (BUMS), Birjand, Iran
| | - Mitra Abbasifard
- Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.,Department of Internal Medicine, Ali-Ibn Abi-Talib Hospital, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
| | - Muhammed Majeed
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
| | - Thomas P Johnston
- Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri, USA
| | - Amirhossein Sahebkar
- Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.,Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.,School of Medicine, The University of Western Australia, Perth, Australia.,Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
5
|
Abbas AS, Hardy N, Ghozy S, Dibas M, Paranjape G, Evanson KW, Reierson NL, Cowie K, Kamrowski S, Schmidt S, Tang Y, Davis AR, Touchette JC, Kallmes KM, Hassan AE, Tarchand R, Mehta M, Pederson JM, Abdelmegeed M. Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: A systematic review. Clin Neurol Neurosurg 2022; 213:107140. [PMID: 35091255 PMCID: PMC8782728 DOI: 10.1016/j.clineuro.2022.107140] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 01/19/2022] [Accepted: 01/20/2022] [Indexed: 12/28/2022]
Abstract
Objective Recent studies suggest that the clinical course and outcomes of patients with coronavirus disease 2019 (COVID-19) and myasthenia gravis (MG) are highly variable. We performed a systematic review of the relevant literature with a key aim to assess the outcomes of invasive ventilation, mortality, and hospital length of stay (HLoS) for patients presenting with MG and COVID-19. Methods We searched the PubMed, Scopus, Web of Science, and MedRxiv databases for original articles that reported patients with MG and COVID-19. We included all clinical studies that reported MG in patients with confirmed COVID-19 cases via RT-PCR tests. We collected data on patient background characteristics, symptoms, time between MG and COVID-19 diagnosis, MG and COVID-19 treatments, HLoS, and mortality at last available follow-up. We reported summary statistics as counts and percentages or mean±SD. When necessary, inverse variance weighting was used to aggregate patient-level data and summary statistics. Results Nineteen studies with 152 patients (mean age 54.4 ± 12.7 years; 79/152 [52.0%] female) were included. Hypertension (62/141, 44.0%) and diabetes (30/141, 21.3%) were the most common comorbidities. The mean time between the diagnosis of MG and COVID-19 was7.0 ± 6.3 years. Diagnosis of COVID-19 was confirmed in all patients via RT-PCR tests. Fever (40/59, 67.8%) and ptosis (9/55, 16.4%) were the most frequent COVID-19 and MG symptoms, respectively. Azithromycin and ceftriaxone were the most common COVID-19 treatments, while prednisone and intravenous immunoglobulin were the most common MG treatments. Invasive ventilation treatment was required for 25/59 (42.4%) of patients. The mean HLoS was 18.2 ± 9.9 days. The mortality rate was 18/152 (11.8%). Conclusion This report provides an overview of the characteristics, treatment, and outcomes of MG in COVID-19 patients. Although COVID-19 may exaggerate the neurological symptoms and worsens the outcome in MG patients, we did not find enough evidence to support this notion. Further studies with larger numbers of patients with MG and COVID-19 are needed to better assess the clinical outcomes in these patients.
Collapse
|
6
|
Myasthenia Gravis-An Analysis of Multimodal Evoked Potentials. Brain Sci 2021; 11:brainsci11081057. [PMID: 34439676 PMCID: PMC8392656 DOI: 10.3390/brainsci11081057] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Revised: 08/06/2021] [Accepted: 08/09/2021] [Indexed: 11/16/2022] Open
Abstract
INTRODUCTION The aim of this study is a comprehensive analysis of the parameters of exogenous evoked potentials (visual, brainstem auditory, and somatosensory) in patients with myasthenia gravis (MG), a prototype of both neuromuscular junction disease and autoimmune disease. The study also seeks to isolate electrophysiological changes that may indicate disorders within the central and/or peripheral nervous system. METHODS A total of forty-two consecutive patients with myasthenia gravis (24 women, 18 men) were included in the study. All of the patients underwent EP examination. MR images were also analyzed. RESULTS In the group of MG patients, the latency of P100 (113.9 ± 13.9; p < 0.0001) VEP, wave III (3.92 ± 0.29; p = 0.015), wave V (5.93 ± 0.32; <0.0001), interlatency III-V (2.00 ± 0.12; p < 0.0001), interlatency I-V (4.20 ± 0.28; p < 0.001) BAEP, and all components of SEP (N9, P10, N13, P16, N20, P22) were significantly longer. Mean wave I and V amplitude BAEP were relatively lower. CONCLUSIONS The results of the study suggest the presence of disturbances in the bioelectric activities of the central and peripheral nervous system in MG patients.
Collapse
|
7
|
Abstract
Neuromuscular respiratory failure can result from any disease that causes weakness of bulbar and/or respiratory muscles. Once compensatory mechanisms are overwhelmed, hypoxemic and hypercapnic respiratory failure ensues. The diagnosis of neuromuscular respiratory failure is primarily clinical, but arterial blood gases, bedside spirometry, and diaphragmatic ultrasonography can help in early assessment. Intensive care unit (ICU) admission is indicated for patients with severe bulbar weakness or rapidly progressing appendicular weakness. Intubation should be performed electively, particularly in patients with dysautonomia. Patients with an underlying treatable cause have the potential to regain functional independence with meticulous ICU care.
Collapse
|
8
|
Rutar Gorišek V, Zupančič D, Zidar J, Horvat Ledinek A. Diffuse large B cell lymphoma mimics myasthenia gravis. Neurol Sci 2019; 41:727-728. [PMID: 31583556 DOI: 10.1007/s10072-019-04074-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Accepted: 09/09/2019] [Indexed: 11/27/2022]
Affiliation(s)
| | - David Zupančič
- Department of Infectious Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia
| | - Janez Zidar
- Clinical Institute of Clinical Electrophysiology, University Medical Centre Ljubljana, Ljubljana, Slovenia
| | | |
Collapse
|
9
|
A Co-Occurrence of Serologically Proven Myasthenia Gravis and Pharyngeal-Cervical-Brachial Variant of Guillain-Barré Syndrome. Case Rep Neurol Med 2019; 2019:4695010. [PMID: 31080681 PMCID: PMC6476010 DOI: 10.1155/2019/4695010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Accepted: 03/27/2019] [Indexed: 11/17/2022] Open
Abstract
We report on a co-occurrence case of ocular myasthenia gravis with exacerbation leading to myasthenic crisis in addition to pharyngeal-cervical-brachial variant of Guillain-Barré syndrome in a patient with severe oropharyngeal dysphagia and acute respiratory failure.
Collapse
|
10
|
Prabhakar H, Ali Z. Intensive Care Management of the Neuromuscular Patient. TEXTBOOK OF NEUROANESTHESIA AND NEUROCRITICAL CARE 2019. [PMCID: PMC7120052 DOI: 10.1007/978-981-13-3390-3_5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Neuromuscular emergencies are a distinct group of acute neurological diseases with distinct characteristic presentations. Patients who suffer from this group of diseases are at immediate risk of losing protection of their native airway as well as aspirating orogastric contents. This is secondary to weakness of the muscles of the oropharynx and respiratory muscles. Although some neuromuscular emergencies such as myasthenia gravis or Guillain-Barré syndrome are well understood, others such as critical illness myopathy and neuropathy are less well characterized. In this chapter, we have discussed the pathophysiology, diagnostic evaluation, and management options in patients who are admitted to the intensive care unit. We have also emphasized the importance of a thorough understanding of the use of pharmacological anesthetic agents in this patient population.
Collapse
Affiliation(s)
- Hemanshu Prabhakar
- Department of Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, India
| | - Zulfiqar Ali
- Division of Neuroanesthesiology, Department of Anesthesiology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir India
| |
Collapse
|
11
|
French DM, Bridges EP, Hoskins MC, Andrews CM, Nelson CH. Myasthenic Crisis In Pregnancy. Clin Pract Cases Emerg Med 2017; 1:291-294. [PMID: 29849328 PMCID: PMC5965196 DOI: 10.5811/cpcem.2017.5.33404] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2016] [Revised: 04/30/2017] [Accepted: 05/11/2017] [Indexed: 12/28/2022] Open
Abstract
This case reviews the management of a 27-year-old pregnant female in myasthenic crisis. She presented to the emergency department in respiratory distress refractory to standard therapy, necessitating airway and ventilatory support and treatment with plasmapheresis. Myasthenic crisis in the setting of pregnancy is rare and presents unique management challenges for emergency physicians.
Collapse
Affiliation(s)
- David M French
- Medical University of South Carolina, Emergency Medicine, Charleston, South Carolina
| | - E Page Bridges
- Greenville Health System, Emergency Medicine, Greenville, South Carolina
| | - Matthew C Hoskins
- Medical University of South Carolina, Emergency Medicine, Charleston, South Carolina
| | - Charles M Andrews
- Medical University of South Carolina, Emergency Medicine, Charleston, South Carolina.,Medical University of South Carolina, Neurocritical Care, Charleston, South Carolina
| | - Cecil H Nelson
- Medical University of South Carolina, Department of Obstetrics and Gynecology, Charleston, South Carolina
| |
Collapse
|
12
|
Muto K, Matsui N, Unai Y, Sakai W, Haji S, Udaka K, Miki H, Furukawa T, Abe M, Kaji R. Memory B cell resurgence requires repeated rituximab in myasthenia gravis. Neuromuscul Disord 2017; 27:918-922. [PMID: 28694074 DOI: 10.1016/j.nmd.2017.06.012] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Revised: 05/31/2017] [Accepted: 06/19/2017] [Indexed: 11/26/2022]
Abstract
The immunologic effects of rituximab (RTX) in myasthenia gravis (MG) remain to be explored. We aimed to clarify immunologic reactions and their association with response to RTX in MG. Regulatory T cell and B cell profiles of MG patients were monitored. Two patients presenting with generalized MG with anti-acetylcholine receptor antibodies were treated with RTX. The treatment led to sustained clinical improvement, discontinuation of intravenous immunoglobulin or plasma exchange, and reduction of prednisolone and other drugs. One patient was in remission for more than one year, whereas the other patient exhibited deterioration of symptoms within one year. Disease activity was associated with the repopulation of IgD-CD27- and IgD-CD27+ memory B cells. Clinicians should be aware of the possibility that MG ranges in the duration of B cell depletion and additional RTX should be prescribed upon resurgence of memory B cells.
Collapse
Affiliation(s)
- Kohei Muto
- Department of Clinical Neuroscience, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan
| | - Naoko Matsui
- Department of Clinical Neuroscience, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
| | - Yuki Unai
- Department of Clinical Neuroscience, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan
| | - Waka Sakai
- Department of Clinical Neuroscience, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan
| | - Shotaro Haji
- Department of Clinical Neuroscience, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan
| | - Kengo Udaka
- Department of Hematology, Endocrinology and Metabolism, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan
| | - Hirokazu Miki
- Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, Tokushima, Japan
| | - Takahiro Furukawa
- Department of Clinical Neuroscience, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan
| | - Masahiro Abe
- Department of Hematology, Endocrinology and Metabolism, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan
| | - Ryuji Kaji
- Department of Clinical Neuroscience, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan
| |
Collapse
|
13
|
Salado-Font SM, López-Muñoz F, Povedano-Montero FJ, Labella Quesada F. Bibliometric analysis of the scientific production as regards statin use for ophthalmological symptoms of myasthenia gravis. ACTA ACUST UNITED AC 2017; 92:464-471. [PMID: 28318833 DOI: 10.1016/j.oftal.2017.01.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Revised: 01/24/2017] [Accepted: 01/25/2017] [Indexed: 11/28/2022]
Abstract
INTRODUCTION The first symptoms of myasthenia gravis (MG) usually involve weakness of the ocular muscles, making it relevant that ophthalmologists have updated information on studies as regards its relationship with the consumption of drugs, such as statins. MATERIALS AND METHODS A bibliometric analysis was performed using the Scopus database and by a search strategy in the selection of documents containing descriptors related to statins in the «Title» («TI») field and the descriptors «ophthalm *', «myast *', «visual *' in other fields of the document (period 1986-2015). RESULTS The results showed that, while the number of scientific publications on ocular effects of statins has grown lineally (n=838; y=2.267x-4507.1; r=0.7221; time of duplication: 4.66 years, and rate of annual growth: 50.06%), the specific publications about MG have experienced an exponential growth (n=38; y=2E-262e0.3001x; r=0.3892; time of duplication: 2.95 years, and rate of annual growth: 46.25%) without reaching the saturation postulated in Price theory of the expansion of the scientific literature. The majority of publications relating to MG are reports of cases linked to a worsening of the MG symptoms, and simvastatin and atorvastatin are the agents mentioned in most of the publications. CONCLUSIONS These results should enable ophthalmologists to expand their knowledge concerning the evolution of studies on statins and MG, pointing out the relevance of such causal relationships.
Collapse
Affiliation(s)
- S M Salado-Font
- Vicerrectorado de Innovación, Universidad Camilo José Cela, Madrid, España.
| | - F López-Muñoz
- Facultad de Salud, Universidad Camilo José Cela, Madrid, España; Instituto de Investigación, Hospital 12 de Octubre, Madrid, España; Red de Investigación Cooperativa en Salud (RETICS-Red de Trastornos Adictivos), Instituto de Salud Carlos III, Madrid, España
| | | | - F Labella Quesada
- Vicedecanato de Ordenación Académica y Estudiantes, Facultad de Medicina, Universidad de Córdoba, Córdoba, España
| |
Collapse
|
14
|
Rodolico C, Parisi D, Portaro S, Biasini F, Sinicropi S, Ciranni A, Toscano A, Messina S, Musumeci O, Vita G, Girlanda P. Myasthenia Gravis: Unusual Presentations and Diagnostic Pitfalls. J Neuromuscul Dis 2016; 3:413-418. [DOI: 10.3233/jnd-160148] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Carmelo Rodolico
- Department of Clinical and Experimental Medicine - University of Messina, Messina, Italy
| | - Daniela Parisi
- Department of Clinical and Experimental Medicine - University of Messina, Messina, Italy
| | | | - Fiammetta Biasini
- Department of Clinical and Experimental Medicine - University of Messina, Messina, Italy
| | - Stefano Sinicropi
- Department of Clinical and Experimental Medicine - University of Messina, Messina, Italy
| | - Annamaria Ciranni
- Department of Clinical and Experimental Medicine - University of Messina, Messina, Italy
| | - Antonio Toscano
- Department of Clinical and Experimental Medicine - University of Messina, Messina, Italy
| | - Sonia Messina
- Department of Clinical and Experimental Medicine - University of Messina, Messina, Italy
| | - Olimpia Musumeci
- Department of Clinical and Experimental Medicine - University of Messina, Messina, Italy
| | - Giuseppe Vita
- Department of Clinical and Experimental Medicine - University of Messina, Messina, Italy
| | - Paolo Girlanda
- Department of Clinical and Experimental Medicine - University of Messina, Messina, Italy
| |
Collapse
|
15
|
Late-onset myasthenia gravis is predisposed to become generalized in the elderly. eNeurologicalSci 2016; 2:17-20. [PMID: 29473057 PMCID: PMC5818137 DOI: 10.1016/j.ensci.2016.02.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2015] [Revised: 02/08/2016] [Accepted: 02/10/2016] [Indexed: 11/23/2022] Open
Abstract
Objective The continuous increase in the number of patients presenting with late-onset myasthenia gravis (LOMG) underscores the need for a better understanding of the clinical course and the establishment of an optimal therapeutic strategy. We aimed to clarify factors associated with clinical outcomes in LOMG. Methods We retrospectively reviewed the clinical profiles of 40 patients with early-onset MG (EOMG) (onset age: 49 years or younger), 30 patients with non-elderly LOMG (onset age: 50–64 years), and 28 patients with elderly LOMG (onset age: 65 years or older) and compared the subgroups according to onset age and thymus status. The evaluated parameters were MGFA classification before treatment, MG-ADL score, complicating diseases, antibody titer, treatment, and MGFA post-intervention status. Results Elderly LOMG patients showed transition to generalized symptoms at a higher frequency and underwent thymectomy less frequently than EOMG and non-elderly LOMG patients (p < 0.001). The frequencies of crisis and plasmapheresis were significantly lower in thymectomized LOMG patients without thymoma than in thymectomized LOMG patients with thymoma or non-thymectomized LOMG patients (p < 0.01, P < 0.05, respectively). However, the outcome was not significantly different. All of the thymectomized LOMG patients without thymoma presenting with hyperplasia or thymic cyst had a favorable clinical course. Conclusions Our study showed that elderly LOMG patients are more prone to severity, suggesting that they require aggressive immunomodulatory therapy. Elderly LOMG patients showed transition to generalized symptoms at a higher frequency. Thymectomized LOMG patients without thymoma showed crisis less frequently. Our study showed that elderly LOMG patients are more prone to severity.
Collapse
Key Words
- AChR, acetylcholine receptor
- ChE-I, cholinesterase inhibitor
- Crisis
- DM, diabetes mellitus
- EOMG, early-onset myasthenia gravis
- Elderly
- Hyperplasia
- IVIg, intravenous immunoglobulin
- LOMG, late-onset myasthenia gravis
- Late-onset myasthenia gravis
- MG-ADL, myasthenia gravis activities of daily living score
- MGFA, Myasthenia Gravis Foundation of America
- PE, plasmapheresis
- PIS, MGFA post-intervention status
- PSL, prednisolone
- Steroid
- Thymectomy
Collapse
|
16
|
Neves AR, Monteiro P, Matos A, Santos Silva I. Anti-MuSK-positive myasthenia gravis diagnosed during pregnancy: new challenges for an old disease? BMJ Case Rep 2015; 2015:bcr-2014-207708. [PMID: 25564591 DOI: 10.1136/bcr-2014-207708] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Myasthenia gravis is an autoimmune disorder affecting predominantly women in their reproductive age. The course of the disease during pregnancy is unpredictable, although it is more difficult to manage earlier in the gestation. Myasthenia gravis with antibodies against the muscle-specific receptor tyrosine kinase (anti-MuSK) has been described as a subtype of disease with more localised clinical features and a poorer response to treatment than acetylcholine receptor antibody (anti-AChR)-positive patients. Few cases have been reported in pregnant women, with deliveries being performed mainly by caesarean section. We report a successful case of vaginal delivery and describe our experience providing the first review of the management of this subtype of disease during pregnancy.
Collapse
Affiliation(s)
- Ana Raquel Neves
- Department of Obstetrics B, Maternidade Bissaya Barreto-Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
| | - Pitorra Monteiro
- Department of Obstetrics B, Maternidade Bissaya Barreto-Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
| | - Anabela Matos
- Department of Neurology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal
| | - Isabel Santos Silva
- Department of Obstetrics B, Maternidade Bissaya Barreto-Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
| |
Collapse
|
17
|
Tamburrini A, Tacconi F, Barlattani A, C. Mineo T. An update on myasthenia gravis, challenging disease for the dental profession. J Oral Sci 2015; 57:161-8. [DOI: 10.2334/josnusd.57.161] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Affiliation(s)
- Alessandro Tamburrini
- Thoracic Surgery Division, Multidisciplinary Myasthenia Gravis Unit, Tor Vergata University
| | - Federico Tacconi
- Thoracic Surgery Division, Multidisciplinary Myasthenia Gravis Unit, Tor Vergata University
| | | | - Tommaso C. Mineo
- Thoracic Surgery Division, Multidisciplinary Myasthenia Gravis Unit, Tor Vergata University
| |
Collapse
|